Genetic Subtype, Genomic Alterations Linked to Relapse in Leukemia
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 22, 2024 -- Genetic subtype, aneuploidy patterns, and genomic alterations are associated with the risk for relapse in childhood acute lymphoblastic leukemia (ALL), according to a study published online Aug. 9 in the Journal of Clinical Oncology.
Ti-Cheng Chang, Ph.D., from St. Jude Children's Research Hospital in Memphis, Tennessee, and colleagues performed genome and transcriptome sequencing of diagnostic and remission samples of children with standard-risk (SR; 1,381 children) or high-risk B-progenitor ALL with favorable cytogenetic features (115 children) to identify genomic determinants of relapse. The case-control study design analyzed 439 children who relapsed and 1,057 who remained in complete remission for five years or longer.
The researchers found an association for genomic subtype with relapse, which occurred in approximately 50 percent of the cases with PAX5-altered ALL (odds ratio [OR], 3.31). Favorable survival was seen in association with gain of chromosome 10 with disomy of chromosome 7 (OR, 0.27; St. Jude Children's Research Hospital validation cohort: OR, 0.22), while disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16; validation cohort OR, 21.32) within high-hyperdiploid ALL. Genomic alterations were associated with relapse in a subtype-dependent manner and were also associated with presence of minimal residual disease.
"As discussions about deintensification of therapy are underway, it is essential to comprehensively genotype newly diagnosed patients with SR ALL to accurately tailor the intensity of therapy to minimize the toxicity without increasing the risk of relapse," the authors write.
Several authors disclosed ties to relevant organizations.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia
WEDNESDAY, April 30, 2025 -- For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless...
Disparities Identified in Leukemia Incidence, Mortality in Florida
TUESDAY, March 25, 2025 -- There are racial and geographic disparities in the incidence of and mortality from adult leukemia in Florida, where the incidence of leukemia is the...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.